Claudio Laudani on Comparison of Target and Non-target Vessel Revascularization for Recurrent ACS
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:
”Patients undergoing repeat revascularization for recurrent acute coronary syndrome represent a particularly high-risk population, yet limited data exist on whether outcomes differ between target-vessel and non-target-vessel revascularization.
In our latest study from the CAST Registry, published in Journal of Cardiovascular Medicine, we analyzed 299 patients undergoing repeat PCI for ACS, and compared the long-term outcomes of patients undergoing TVR vs. non-TVR.
Alos, we explored the predictors of long-term adverse events in this high-risk population.
In our study, we found that:
- Patients undergoing repeat PCI for ACS represent a very high risk population, with most of the patients presenting with not at target LDL levels.
- This high thrombotic risk is also reflected in the follow-up event rate, as MACE rates were as high as 37% at 3 years.
- There were no significant differences between TVR and non-TVR, suggesting that recurrent ischemia is the reflection of a systematic high thrombotic burden phenotype rather than local procedure failure.
- Variables of procedural complexity were the main predictors of long-term events, including cardiogenic shock at presentation, longer fluoroscopy time, and LAD involvement.
Overall, our data highlight that patients undergoing repeat PCI require a more aggressive treatment to prevent long-term adverse events.”
Read the full article here.
Article: Long-term outcomes of percutaneous coronary intervention for recurrent events in patients undergoing target-vessel vs. nontarget-vessel revascularization
Authors: Simone Finocchiaro, Maria Sara Mauro, Claudio Laudani, Davide Landolina, Placido Maria Mazzone, Antonino Imbesi, Marco Spagnolo, Antonio Greco, Francesco Nasisi, Davide Capodanno
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC